Connection
Michael Graner to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Michael Graner has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.149 |
|
|
|
-
Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J. 2007 Jul; 21(9):2173-84.
Score: 0.060
-
Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer. 2004 Jun 10; 110(2):251-9.
Score: 0.050
-
He L, Feng H, Raymond A, Kreeger M, Zeng Y, Graner M, Whitesell L, Katsanis E. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol Immunother. 2001 Mar; 50(1):31-40.
Score: 0.039